Efficacy of Shenqi Fuzheng Injection combined with chemotherapy in treatment of acute myeloid leukemia and its effect on body's immune function / 中草药

ABSTRACT

Objective: To observe the clinical efficacy of Shenqi Fuzheng Injection (SFI) combined with chemotherapy in the treatment of acute myeloid leukemia (AML) and the effect on body's immune function, and to explore the function and mechanism of adjuvant chemotherapy with SFI. Methods: One hundred and twelve patients were divided into two groups the treatment group (n = 54) treated with DA protocol plus SFI and the control group (n = 58) treated with DA protocol alone. We observed the remission rate, mortality, the time of myelosuppression, the changes of T lymphocyte subsets; and the side-effects of chemotherapy for the patients in the two groups. Results: Comparing the remission rate and mortality rate of the patients between the two groups, there was no statistically significant difference (P > 0.05). The side-effects of the patients in the treatment group were more significantly reduced than those of the patients in the control group (P +/CD4+ cells, and higher cell rates of CD4+/CD8+ (P < 0.05). Conclusion: The SFI could shorten the time of myelosuppression induced by the chemotherapy in the treatment of AML, regulate the level of T lymphocyte subsets, enhance the active immune function of body, and reduce the relative side-effects of chemotherapy.